28 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
-party payors and the medical community and our ability and our distribution and marketing partners’ ability to obtain coverage and adequate
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability and our … acceptance of our product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
acceptance of our product candidates among physicians, patients, patient advocacy groups, third-party payors and the medical community and our ability … relationships with suppliers, customers and others, (iv) the impact of the company’s operations on the community and the environment, (v
8-K
EX-99.2
4yfvo0c33cg3zildk
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
0zjlcocn
28 Feb 24
Annual report
7:33am
6-K
EX-99.4
oijneef7klnans
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.3
aywg21tu crla0j
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.4
8036aw5hujm
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
82167unm 8lpq309nljm
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
v3a7x n9d7wphy3
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
goclge bi
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.4
wbxft6
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
8a1woud
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
424B7
tjgs ro4ryku9g7jqp
5 May 22
Prospectus with selling stockholder info
12:00am
F-3ASR
nydi88tk1 qao
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
20-F
fbnzvd
25 Mar 21
Annual report (foreign)
7:01am
20-F
EX-2.4
idgtws2bs
25 Mar 21
Annual report (foreign)
7:01am